File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma

TitleSociety for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
Authors
Keywordsantineoplastic protocols
guidelines as topic
immunotherapy
liver neoplasms
Issue Date2021
PublisherBMJ Publishing Group: Open Access Journals. The Journal's web site is located at http://www.immunotherapyofcancer.org/
Citation
Journal for ImmunoTherapy of Cancer, 2021, v. 9 n. 9, p. article no. e002794 How to Cite?
AbstractPatients with advanced hepatocellular carcinoma (HCC) have historically had few options and faced extremely poor prognoses if their disease progressed after standard-of-care tyrosine kinase inhibitors (TKIs). Recently, the standard of care for HCC has been transformed as a combination of the immune checkpoint inhibitor (ICI) atezolizumab plus the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab was shown to offer improved overall survival in the first-line setting. Immunotherapy has demonstrated safety and efficacy in later lines of therapy as well, and ongoing trials are investigating novel combinations of ICIs and TKIs, in addition to interventions earlier in the course of disease or in combination with liver-directed therapies. Because HCC usually develops against a background of cirrhosis, immunotherapy for liver tumors is complex and oncologists need to account for both immunological and hepatological considerations when developing a treatment plan for their patients. To provide guidance to the oncology community on important concerns for the immunotherapeutic care of HCC, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a clinical practice guideline (CPG). The expert panel drew on the published literature as well as their clinical experience to develop recommendations for healthcare professionals on these important aspects of immunotherapeutic treatment for HCC, including diagnosis and staging, treatment planning, immune-related adverse events (irAEs), and patient quality of life (QOL) considerations. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers treating patients with HCC.
Persistent Identifierhttp://hdl.handle.net/10722/304990
ISSN
2023 Impact Factor: 10.3
2023 SCImago Journal Rankings: 3.728
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorGreten, TF-
dc.contributor.authorAbou-Alfa, GK-
dc.contributor.authorCheng, AL-
dc.contributor.authorDuffy, AG-
dc.contributor.authorEl-Khoueiry, AB-
dc.contributor.authorFinn, RS-
dc.contributor.authorGalle, PR-
dc.contributor.authorGoyal, L-
dc.contributor.authorHe, AR-
dc.contributor.authorKaseb, AO-
dc.contributor.authorKelley, RK-
dc.contributor.authorLencioni, R-
dc.contributor.authorLujambio, A-
dc.contributor.authorMabry Hrones, D-
dc.contributor.authorPinato, DJ-
dc.contributor.authorSangro, B-
dc.contributor.authorTroisi, RI-
dc.contributor.authorWilson Woods, A-
dc.contributor.authorYau, T-
dc.contributor.authorZhu, AX-
dc.contributor.authorMelero, I-
dc.date.accessioned2021-10-05T02:38:09Z-
dc.date.available2021-10-05T02:38:09Z-
dc.date.issued2021-
dc.identifier.citationJournal for ImmunoTherapy of Cancer, 2021, v. 9 n. 9, p. article no. e002794-
dc.identifier.issn2051-1426-
dc.identifier.urihttp://hdl.handle.net/10722/304990-
dc.description.abstractPatients with advanced hepatocellular carcinoma (HCC) have historically had few options and faced extremely poor prognoses if their disease progressed after standard-of-care tyrosine kinase inhibitors (TKIs). Recently, the standard of care for HCC has been transformed as a combination of the immune checkpoint inhibitor (ICI) atezolizumab plus the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab was shown to offer improved overall survival in the first-line setting. Immunotherapy has demonstrated safety and efficacy in later lines of therapy as well, and ongoing trials are investigating novel combinations of ICIs and TKIs, in addition to interventions earlier in the course of disease or in combination with liver-directed therapies. Because HCC usually develops against a background of cirrhosis, immunotherapy for liver tumors is complex and oncologists need to account for both immunological and hepatological considerations when developing a treatment plan for their patients. To provide guidance to the oncology community on important concerns for the immunotherapeutic care of HCC, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a clinical practice guideline (CPG). The expert panel drew on the published literature as well as their clinical experience to develop recommendations for healthcare professionals on these important aspects of immunotherapeutic treatment for HCC, including diagnosis and staging, treatment planning, immune-related adverse events (irAEs), and patient quality of life (QOL) considerations. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers treating patients with HCC.-
dc.languageeng-
dc.publisherBMJ Publishing Group: Open Access Journals. The Journal's web site is located at http://www.immunotherapyofcancer.org/-
dc.relation.ispartofJournal for ImmunoTherapy of Cancer-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectantineoplastic protocols-
dc.subjectguidelines as topic-
dc.subjectimmunotherapy-
dc.subjectliver neoplasms-
dc.titleSociety for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma-
dc.typeArticle-
dc.identifier.emailYau, T: tyaucc@hku.hk-
dc.identifier.authorityYau, T=rp01466-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1136/jitc-2021-002794-
dc.identifier.pmid34518290-
dc.identifier.pmcidPMC8438858-
dc.identifier.scopuseid_2-s2.0-85115015817-
dc.identifier.hkuros326274-
dc.identifier.volume9-
dc.identifier.issue9-
dc.identifier.spagearticle no. e002794-
dc.identifier.epagearticle no. e002794-
dc.identifier.isiWOS:000697845700001-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats